AXGN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AX

Mkt Cap

$2.03B

Volume

918.83K

Next Earnings

October 28th

Loading chart

AX

AXGNAxogen, Inc. Common Stock

AXGN

Pay with—

Available Balance0.00

AX

Mkt Cap

$2.09B

Volume

918.83K

Next Earnings

October 28th

Chart Financials Earnings News About Insider Filings

GMED or AXGN: Which Is the Better Value Stock Right Now?In a comparison of two medical instruments stocks, Globus Medical (GMED) and AxoGen (AXGN), both holding a Zacks Rank #2 (Buy), GMED emerges as the superior value option. GMED has a forward P/E of 15.81 compared to AXGN's 73.46, a PEG ratio of 1.27 vs 1.42, and a P/B ratio of 2.22 vs 7.47, earning GMED a Value grade of B while AXGN received an F.Zacks Investment Research · Oct 16, 2026

Here's Why You Should Retain DexCom Stock in Your Portfolio for NowDexCom (DXCM) reported strong Q2 2026 results with gross margin expanding to 64.1% and operating margin at 25.1%, driven by manufacturing efficiencies and G7 15-day product transition. However, near-term profitability could face pressure from Ireland factory ramp-up costs, forex headwinds, and higher oil-linked input costs. The company maintains a Zacks Rank #3 (Hold) rating with shares up 29.4% year-to-date.Zacks Investment Research · Oct 13, 2026

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)AxoGen (AXGN) has declined 22.6% over four weeks and is now in oversold territory with an RSI reading of 27.04, suggesting a potential reversal. Wall Street analysts have raised earnings estimates by 2.2% over the past 30 days, and the stock holds a Zacks Rank #2 (Buy) rating, indicating potential for near-term price appreciation.Zacks Investment Research · Oct 5, 2026

Axogen Enters into Definitive Agreement to Acquire BioCircuit TechnologiesAxogen announced a definitive agreement to acquire BioCircuit Technologies for $200 million in cash, adding NerveTape™, the first FDA-approved sutureless device for peripheral nerve repair. The acquisition is expected to close in Q4 2026 and be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in the first year, while maintaining positive free cash flow. Axogen will fund the purchase through a $208.7 million public stock offering.GlobeNewswire Inc. · Sep 10, 2026

Axogen, Inc. to Participate in Multiple Upcoming Investor ConferencesAxogen, Inc. announced that management will participate in three investor conferences in March 2026: Raymond James 47th Annual Institutional Investors Conference (March 3), Leerink Global Healthcare Conference (March 9), and The Citizens Life Sciences Conference (March 10). The company will present and hold 1x1 investor meetings at these events, with webcasts available on its investor relations website.GlobeNewswire Inc. · Feb 17, 2026

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026Axogen, Inc. (Nasdaq: AXGN), a peripheral nerve repair solutions company, announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026, followed by a management conference call and webcast at 8:00 a.m. ET. The company invites investors to participate via phone or live webcast.GlobeNewswire Inc. · Feb 10, 2026

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common StockAxogen, Inc. announced an upsized underwritten public offering of 4 million shares at $31.00 per share, expected to raise approximately $124 million in gross proceeds. The company plans to use the net proceeds to pay off its term loan facility with Oberland Capital, along with working capital and capital expenditures. The offering is expected to close on January 23, 2026.GlobeNewswire Inc. · Jan 22, 2026

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025Axogen reported preliminary full-year 2025 revenue of approximately $225.2 million, representing 20.2% growth over 2024, with Q4 2025 revenue expected at $59.9 million (21.3% increase). The company achieved FDA Biologics License Application approval for Avance® on December 3, 2025, and expects gross margins above 74%. Cash position improved by approximately $6.0 million to $45.5 million by year-end 2025.GlobeNewswire Inc. · Jan 12, 2026

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)Axogen received FDA Biologics License Application approval for AVANCE, an acellular nerve scaffold for treating peripheral nerve discontinuities in patients aged 1 month and older, with commercial availability expected in early Q2 2026.GlobeNewswire Inc. · Dec 4, 2025

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law FirmThe Schall Law Firm is investigating potential securities law violations by Axogen, Inc. after the company's stock dropped over 9% following an FDA application extension announcement for its Avance® Nerve Graft.Benzinga · Oct 1, 2025

to start trading

AX

AXGNAxogen, Inc. Common Stock

AXGN

Pay with—

Available Balance0.00

Your PositionYou don't own any AXGN yet.

Related Tickers

Earnings